Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2021: Jan Feb
2021 - 2020 - 2019 - 2018

February 2021 Scleroderma News

Identifying early pulmonary arterial hypertension (PAH) biomarkers in systemic sclerosis (SSc): Machine learning on proteomics from the DETECT cohort. This novel 8-protein biomarker panel has the potential to improve early detection of PAH in SSc patients and may provide novel insights into the pathogenesis of PAH in the context of SSc. PubMed, Eur Respir J, 2020 Dec 17;2002591. (Also see Prognosis of Pulmonary Hypertension)

Osteopontin Protein May Be Cause of Lung Scarring in Scleroderma. Osteopontin may be driving scarring of lung tissue in people with scleroderma associated with interstitial lung disease, a study suggests. Scleroderma News, 12/22/2020. (Also see Pulmonary Fibrosis Diagnosis)

Effect of bosentan in pulmonary hypertension development in systemic sclerosis (SSc) patients with digital ulcers. We concluded that SSc patients with digital ulcers treated with bosentan seems to have less risk to develop pulmonary hypertension and to stabilize carbon monoxide diffusing capacity. PubMed, PLoS One, 2020 Dec 10;15(12):e0243651. (Also see Tracleer (Bosentan))

More Than 40% of Scleroderma Patients Have Bone Density Loss, Study Finds. More than 40% of scleroderma patients are diagnosed with osteopenia or osteoporosis and the risk is increased by time from first symptom and with the use of immunosuppressants, a study has found. Scleroderma News, 12/15/2020. (Also see Osteoporosis)

Does sublingual microscopy correlate with nailfold videocapillaroscopy in systemic sclerosis (SSc)? Nailfold and sublingual microscopy can identify a loss of capillary density in SSc patients. PubMed, Clin Rheumatol, 01/07/2021. (Also see Vascular Involvement and Nailfold Capillaroscopy)

The hard problem: Mechanotransduction perpetuates the myofibroblast phenotype in scleroderma fibrosis. Fibrotic myofibroblasts possess an intrinsically activated pro-adhesive signaling pathway, and that this contributes to the perpetuation of pathological fibrosis. PubMed, Wound Repair Regen, 01/07/2021. (Also see Fibroblasts)

Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. Analysis of immune cell parameters has identified abnormalities that likely reflect disease pathogenesis and that are candidate biomarkers for sub-classification and targeted treatment. PubMed, Arthritis Res Ther, 2021 Jan 6;23(1):10. (Also see B Cells and T Cells)

TMB-003 Therapy to Reduce Scarring Wins FDA Orphan Drug Designation. Scleroderma treatment TMB-003 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). Scleroderma News, 01/14/2021. (Also see Clinical Trials)

Serum markers of pulmonary epithelial damage in systemic sclerosis–associated interstitial lung disease (SSc-ILD) and disease progression. Our results suggest serum KL-6 predicts decline in lung function in SSc, suggesting its clinical utility in risk stratification for progressive SSc-ILD. PubMed, Respirology, 12/17/2020. (Also see Pulmonary Fibrosis)

A Real–World Experience of Mycophenolate Mofetil (MMF) for Systemic Sclerosis (SSc): A Retrospective Multicenter Observational Study. This real-world based study supports the role of MMF in the stabilization of lung function and the improvement in skin thickness with an acceptable safety profile in patients with SSc. PubMed, Arch Rheumatol, 2020 Jan 13;35(3):366-375. (Also see Immunosuppressants)

Go to Scleroderma Medical News: January 2021

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.